Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting Regorafenib-Induced Toxicity through Inhibition of Gut Microbial β-Glucuronidases

30 Oct 2019

Abstract excerpt

Regorafenib (Stivarga) is an oral small molecule kinase inhibitor used to treat metastatic colorectal cancer, hepatocellular carcinomas, and gastrointestinal stromal tumors. Diarrhea is one of the most frequently observed adverse reactions associated with regorafenib. This toxicity may arise from the reactivation of the inactive regorafenib-glucuronide to regorafenib by gut microbial β-glucuronidase (GUS) enzymes...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biochemical and Molecular Research
Share to Colorectal Cancer Treatments and Studies
Share to Pharmacological Effects of Natural Compounds

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31663730
DOI: 10.1021/acschembio.9b00663

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting Regorafenib-Induced Toxicity through Inhibition of Gut Microbial β-GlucuronidasesPMID 31663730Read ↗

Structural basis for the regulation of β-glucuronidase expression by human gut Enterobacteriaceae.Semantic proximity Read ↗

Emerging roles for UDP-glucuronosyltransferases in drug resistance and cancer progressionSemantic proximity Read ↗

Metagenomics Combined with Activity-Based Proteomics Point to Gut Bacterial Enzymes that Reactivate MycophenolateSemantic proximity Read ↗

Entropy-driven binding of gut bacterial β-glucuronidase inhibitors ameliorates irinotecan-induced toxicitySemantic proximity Read ↗

Identify old drugs as selective bacterial β‐GUS inhibitors by structural‐based virtual screening and bio‐evaluationsSemantic proximity Read ↗

Discovery of α-l-arabinopyranosidases from human gut microbiome expands the diversity within glycoside hydrolase family 42.Semantic proximity Read ↗

Arylsulfamates inhibit colonic <i>Bacteroides</i> growth through lipid kinases and not sulfatasesSemantic proximity Read ↗

Discovery and validation of 2-styryl substituted benzoxazin-4-ones as a novel scaffold for rhomboid protease inhibitors.Semantic proximity Read ↗

Gastrointestinally distributed UDP-glucuronosyltransferase 1A10, which metabolizes estrogens and nonsteroidal anti-inflammatory drugs, depends upon phosphorylation.Semantic proximity Read ↗

Discovery of cell-active small molecule inhibitors of UDP-galactose 4’-epimeraseSemantic proximity Read ↗

Mechanism-based inhibitors of glycosidases: design and applications.Semantic proximity Read ↗

Characterization of raloxifene glucuronidation: potential role of UGT1A8 genotype on raloxifene metabolism in vivo.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.